Pharmacological principles for safe benzodiazepine and Z-drug dose reduction
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index; 49 of the 156 sources its claims cite were checked for support.
Abstract
Many guidelines recommend deprescribing benzodiazepines and z-drugs in most long-term users. Due to physical dependence in those using medication as prescribed (distinct from addiction), discontinuation can be difficult and is often unsuccessful, as withdrawal symptoms can be severe and long-lasting, especially after long-term use. There is a lack of clarity on how to taper patients in a tolerable manner that minimizes discomfort. Current guidelines vary with some suggesting linear reductions (e.g. 1 mg every 1-4 weeks) and some proportionate reductions (e.g. 5%-10% of the most recent dose per month, with smaller reductions as the dose decreases). The shape of the relationship between dose of benzodiazepine and activity at gamma-aminobutyric acid-A (GABA-A) receptors is hyperbolic: steeply inclining at low doses, flattening at higher doses. Consequently, linear dose reductions produce increasingly large changes in receptor occupancy, predicting escalating withdrawal effects, while hyperbolic or proportionate dose reductions produce linear reductions in pharmacological effect. Slower tapering (over months and years) may be more successful than tapering over days or weeks. In practice, rate of tapering should be adjusted according to severity of withdrawal effects. Final doses for some people will need to be very small (equivalent to as little as 0.2 mg of diazepam, or less) so that the last 'step down' to zero is not larger than prior tolerated reductions in terms of pharmacological effects. Liquids or compounded formulations of medication can be helpful at low doses to make small reductions. Guidelines should recommend hyperbolic tapering while awaiting randomized trials comparing linear with hyperbolic tapering.
Overview
CoChat Summary
TL;DR
This narrative review argues that benzodiazepine and z-drug tapering should follow hyperbolic/proportionate dose reductions because the dose–GABA-A occupancy relationship is hyperbolic, so linear reductions produce increasingly large pharmacological effects and likely worsening withdrawal. It recommends slow, symptom-guided tapering with very small final doses, while noting that randomized trials comparing linear and hyperbolic tapering are still lacking.
Key findings
- Benzodiazepine dose and GABA-A occupancy are hyperbolically related: reducing diazepam by fixed 12.5 mg steps from 50 mg produces progressively larger occupancy drops—6.6 percentage points (50 to 37.5 mg), 10.0 p.p. (37.5 to 25 mg), 16.7 p.p. (25 to 12.5 mg), and 33.6 p.p. (12.5 to 0 mg). At low doses, 5 to 0 mg changes occupancy by 16.8 p.p., exceeding the 13.3 p.p. change from 100 to 50 mg.
- Linear tapering is often unsuccessful: one trial found 90% of linearly tapered patients experienced withdrawal symptoms, with 32% on long half-life benzodiazepines and 42% on short half-life benzodiazepines unable to cease medication; only 36% successfully stopped after a 4-week taper at 15-month follow-up. A systematic review of 35 studies found best results with a 10-week taper, though 31% still could not stop.
- Hyperbolic/proportionate tapering—approximately 5%–10% of the most recent dose every 1–2 weeks—produces roughly linear reductions in GABA-A occupancy (about 1–2 percentage points per step) and is recommended over linear tapering. Final doses may need to be very small, equivalent to as little as 0.2 mg diazepam or less, so the last step to zero is not larger than previously tolerated reductions.
- Adding psychological support to tapering increased cessation rates (OR 1.82) with sustained benefit at follow-up (OR 1.88), whereas gradual tapering alone had a larger effect versus routine care (OR 6); no medication is approved for benzodiazepine withdrawal, and the ASAM panel found no single medication with enough data to recommend.
Methods
- Narrative review of benzodiazepine withdrawal syndrome and commonly used tapering guidance from UK and US authorities, plus review of basic benzodiazepine pharmacology and withdrawal neurobiology.
- Targeted literature searches on PubMed and Google Scholar for relevant domains; principles for tapering were developed from this understanding.
- Focused on patients taking benzodiazepines as prescribed without benzodiazepine use disorder, stated to account for 98% of benzodiazepine users; management of addiction was outside scope.
Limitations
- The paper states that PET imaging data used to model the dose–occupancy curve come from non-human primates rather than humans, represent single doses and population averages, and obscure inter-individual variability in receptor sensitivity, binding affinity, and pharmacodynamic response.
- The paper states that no empirical studies have directly tested linear versus hyperbolic tapering; the recommendation remains a biologically plausible inference from receptor theory and clinical experience.
- The paper states that modeling assumes steady-state pharmacokinetics and linear elimination, which may be disrupted by illness, polypharmacy, or metabolic variability; evident from the text, this is a narrative review without a randomized trial or systematic meta-analysis comparing tapering strategies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
35 Valid · 5 Not valid · 57 Not checked · 26 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Guidelines universally recommend tapering benzodiazepines, yet there is no definitive method, and most advice is based on expert consensus rather than empirical evidence or pharmacological principles, resulting in conflicting advice (Brunner et al., 2025; Pollmann, Murphy, Bergman, & Gardner, 2015).”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Introduction
What the sources say
- Partly supportedcites Brunner et al., 2025 sourceExperimental — accuracy not yet measured
The Summary of Recommendations says tapering is indicated for patients likely to be physically dependent when the risks of continued benzodiazepine use outweigh the benefits. The Tapering Process section says most existing guidance emphasizes gradual dose reductions for dependent patients, not that guidelines universally recommend tapering for all patients. (LLM, conf=0.88)
- Partly supportedcites Pollmann, Murphy, Bergman, & Gardner, 2015 sourceExperimental — accuracy not yet measured
In Results > Deprescribing strategies (page unavailable), the review says that most review articles and clinical practice guidelines—60 of 65 (92%)—recommended gradual dose reduction. This supports tapering as a common recommendation, but the combined figure does not establish that guidelines universally recommend it. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Severe withdrawal from physical dependence alone does not imply addiction.”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Methods
What the sources say
- Supportedcites Horowitz & Taylor, 2023 source
The paper's central argument is exactly this separation: it states that 'dependence is not the same as addiction' and that withdrawal effects occur irrespective of whether drugs are taken as prescribed or misused, with tolerance and withdrawal 'not necessarily indicate[ing] the presence of an addiction'. Severity is covered too: the copy notes that 'when these withdrawal symptoms are intolerable, patients can be unable to stop these medications, even when they desire to do so', while still classing such drugs (e.g. antidepressants) as dependence-forming but not addictive, and warns that people struggling with withdrawal 'can be accused of addiction or misuse'. Thus severe withdrawal from physical dependence alone does not imply addiction is the source's own thesis, not merely a quoted DSM-5 line it reproduces. (LLM, conf=0.88)
- Partly supportedcites O’Brien, 2011 sourceExperimental — accuracy not yet measured
In the Abstract (page unavailable), the paper distinguishes physical dependence and withdrawal from addiction, which it describes as compulsive drug-seeking. It also says withdrawal symptoms alone do not count toward a substance-use diagnosis during appropriate medical treatment. It does not specifically address severe withdrawal, so that qualifier is not directly supported. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Only 36% of patients were able to successfully stop their benzodiazepine in a similar trial with a 4-week taper at 15-month follow-up (Voshaar et al., 2003).”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Existing evidence for linear versus hyperbolic tapering
What the sources say
- Partly supportedcites Voshaar et al., 2003 sourceExperimental — accuracy not yet measured
The Intervention section describes a four-week taper, so that part matches. But Table 2 reports outcomes at three months, not 15 months: successful discontinuation in the taper-only group was 51% of the whole assigned group or 62% of those who completed follow-up, not 36%. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, clinical studies have reported that linear tapering is unsuccessful for a significant proportion of patients.”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Existing evidence for linear versus hyperbolic tapering
What the sources say
- Not matchedcites Schweizer et al., 1990
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Voshaar et al., 2003 source
The Intervention section describes a scheduled reduction of the daily diazepam dose by 25% each week over four weeks, with an option to split the final step. The Results report successful discontinuation in 62% of the tapering-only group, meaning a substantial proportion did not discontinue. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
Every source the paper cites for this claim was checked and supports it.
In the paper
“A survey of specialized deprescribing clinics around the world report using hyperbolic tapering as their main approach to safely stopping psychiatric drugs, including benzodiazepines (Cooper et al., 2023).”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Existing evidence for linear versus hyperbolic tapering
What the sources say
- Supportedcites Cooper et al., 2023 source
The Results (Descriptions of services and common characteristics; page unavailable) describe gradual, broadly hyperbolic tapering as a commonly reported practice, while specifying that some services used broadly hyperbolic strategies. The same section says most services worked with a range of psychotropic medications, including benzodiazepines; the Discussion identifies this as an international survey of 13 services. (LLM, conf=0.89)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
77 more claims · 22 with their cited sources checked
Create a free account to see all 123 claims and to verify the 2 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 9
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Implementation in clinical practice > Small dose formulations
“clonazepam (0.125 mg, 7.8% occupancy)”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Introduction
“| Clonazepam | 0.25 mg | 18–50 | 0.5 mg, 2 mg | 0.5 mg/5 mL,2 mg/5 mL | 9.2b |”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Implementation in clinical practice > Small dose formulations
“temazepam (2.5 mg, 5.3% occupancy)”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Introduction
“| Temazepam | 10 mg | 8–22 | 10 mg, 20 mg | 10 mg/5 mL | 4.8b |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Introduction
“| Lorazepam | 0.5 mg | 10–20 | 0.5 g, 1 mg, 2.5 mg | 1 mg/mL | 4.8b |”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Implementation in clinical practice > Small dose formulations
“lorazepam (0.125 mg, 5.3% GABA-A occupancy)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Implementation in clinical practice > Small dose formulations
“lorazepam (0.125 mg, 5.3% GABA-A occupancy)”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Introduction
“| Lorazepam | 0.5 mg | 10–20 | 0.5 g, 1 mg, 2.5 mg | 1 mg/mL | 4.8b |”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“A systematic review of 35 studies found the best results with a 10-week taper, though 31% still could not stop (Cantopher, Olivieri, Cleave, & Edwards, 1990; Denis, Fatseas, Lavie, & Auriacombe, 2005).”
Cited work 10.1002/14651858.cd005194 · retracted 2013-06-18 · notice 10.1002/14651858.cd005194.pub3 · this paper published 2026
Citations
Cites
1 retracted
Denis, C., Fatséas, M., Lavie, E., & Auriacombe, M. (2005) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005194 · Cited by 3 · cited 2×
“A systematic review of 35 studies found the best results with a 10-week taper, though 31% still could not stop (Cantopher, Olivieri, Cleave, & Edwards, 1990; Denis, Fatseas, Lavie, & Auriacombe, 2005).”
RetractedA Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174 · cited 2×
“This table, based on the E max equation of best fit derived from the data in Brouillet et al. (1991), after conversion to human equivalent dosage (Nair & Jacob, 2016”
InfluentialBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., & Roth, T. (2003) · Sleep · doi:10.1093/sleep/26.7.793 · Cited by 630 · cited 1×
“While the benefits of benzodiazepines in acute syndromes are unchallenged for psychiatric indications (Krystal et al., 2003; Roth et al., 2005), the dangers of long-term prescribing are widely accepted (Olfson, King, & Schoenbaum, 2015).”
Benzodiazepine use and risk of Alzheimer's disease: case-control study
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B. (2014) · BMJ · doi:10.1136/bmj.g5205 · Cited by 558
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 6×
“Reduced GABA transmission allows increased excitatory activity, as neurotransmitters like glutamate act with less opposition (Ashton, 2005), perhaps explaining symptoms such as panic, anxiety, tachycardia, diaphoresis, and typical of excitatory states.”
InfluentialThe amnesic action of benzodiazepines in man
Lister, R. G. (1985) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(85)90034-x · Cited by 448 · cited 1×
“Longer-term use is associated with a number of physical and cognitive risks, including physical dependence, tolerance, loss of efficacy, falls, and fractures ( Donnelly et al., 2017) and memory disturbance (Lister, 1985).”
Kapur, J., & Macdonald, R. L. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-19-07532.1997 · Cited by 427 · cited 1×
“Seizure threshold shows a hyperbolic relationship to dose in zebrafish (Gupta, Kho-bragade, & Shingatgeri, 2014), rats (Kapur & Macdonald, 1997), and non-human primates (Bottlaender et al., 1994) (Figure 3b).”
Benzodiazepine Use and Misuse Among Adults in the United States
Maust, D. T., Lin, L. A., & Blow, F. C. (2019) · Psychiatric Services · doi:10.1176/appi.ps.201800321 · Cited by 337
Research works printed but not linked: 11
- White, 2015, Handbook of drug administration via enteral feeding tubes (third)
- Dhaliwal, 2025, Diazepam
- Parsons, 2012, Dependence on benzodiazepines or Z-drugs: Having that conversation, The Pharmaceutical Journal, 289, 399
- Dubinsky, 2002, Nonbenzodiazepine anxiolytic, Pharmacology, 303, 777
- 2018, MOC guidelines for tablet crushing in patients with swallowing difficulties
- Guy, 2019, Guidance for psychological therapists: Enabling conversations with clients taking or withdrawing from prescribed psychiatric drugs
- Shapiro, 2025, The psychopharmacology blue book
- 2004, Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
- Root, 2011, Pharmaceutical issues when crushing, opening or splitting Oral dosage forms, Royal Pharmaceutical Society, 1, 1
- Horowitz, 2024, The Maudsley deprescribing guidelines in psychiatry: Antidepressants, benzodiazepines, Gabapentinoids and Z-drugs
- Harriman, 2014, Deprescribing medication for frail elderly patients: Survey of Vancouver family physicians, Canadian Family Physician Medecin de famille canadien, 60, S16
Metadata
- Authors
- Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D.
- Affiliations
- North East London NHS Foundation Trust (GB)
- Benzodiazepine Information Coalition
- University of Manitoba (CA)
- Psychotropic Deprescribing Council
- University of California, Irvine (US)
- Rigshospitalet (DK)
- Trinity College Dublin (IE)
- University of Colorado Anschutz (US)
- Columbia University (US)
- Corresponding author
- Horowitz, Mark
- ORCID
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2026
- Volume
- 56
- Pages
- e198-e198
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- PMC
- PMC13280687
- OpenAlex
- W7165192235
- Cited by
- 0
- References
- 81
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Psychological Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepines, Z-drugs, deprescribing, dose reduction, tapering, withdrawal symptoms, physical dependence, chronic drug administration, compounded formulations
- MeSH terms
- Deprescriptions, Drug Tapering, Benzodiazepines, Dose-Response Relationship, Drug, Humans, Substance Withdrawal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological principles for safe benzodiazepine and Z-drug dose reduction. https://app.cochat.ai/papers/10.1017/s0033291726104887
- The paper
- Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D. (2026). Pharmacological principles for safe benzodiazepine and Z-drug dose reduction. Psychological Medicine. https://doi.org/10.1017/s0033291726104887
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.